New TB vaccines enter human trials – hope for millions
NCT ID NCT05547464
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 30 times
Summary
This study tests two experimental vaccines (BNT164a1 and BNT164b1) to prevent tuberculosis (TB) in adults who have already received the BCG vaccine and are HIV-negative. About 497 participants will receive up to three doses to find the safest and most effective dose. The goal is to see if the vaccines are safe and trigger a strong immune response against TB.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Africa Health Research Institute (AHRI)
Mtubatuba, 3935, South Africa
-
CAPRISA eThekweni Clinical Research Site
Berea, 4001, South Africa
-
Centre for Lung Infection and Immunity UCT Lung Institute
Cape Town, 7700, South Africa
-
Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC) (recruiting participants for Part B only)
Maputo, 1102, Mozambique
-
Centro de Investigação em Saúde de Manhiça (CISM) (recruiting participants for Part B only)
Manhiça, 1929, Mozambique
-
Desmond Tutu Health Foundation - Masiphumele Research Office
Cape Town, 7975, South Africa
-
South African Tuberculosis Vaccine Initiative SATVI
Cape Town, 6850, South Africa
-
The Aurum Institute Tembisa CRC Clinic 4
Tembisa, 1632, South Africa
Conditions
Explore the condition pages connected to this study.